Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | PARP1 | P09874 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | AGER | Q15109 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14324876 | 0.92 | KDM4E (0.81) | KDM4ETDP1PARP1ALDH1A1HPGD | |
| SCHEMBL29916420 | 0.86 | KDM4E (0.55) | KDM4ETDP1PARP1ALDH1A1HPGD | |
| SCHEMBL945856 | 0.86 | KDM4E (0.55) | KDM4ETDP1PARP1ALDH1A1HPGD | |
| SCHEMBL3620548 | 0.85 | GRM5 (0.51) | KDM4ETDP1PARP1ALDH1A1HPGD | |
| SCHEMBL16059482 | 0.85 | PARP1 (0.50) | KDM4ETDP1PARP1ALDH1A1HPGD | |
| SCHEMBL31660092 | 0.85 | PARP1 (0.50) | KDM4ETDP1PARP1ALDH1A1HPGD | |
| SCHEMBL29455925 | 0.83 | GRM5 (0.50) | KDM4ETDP1PARP1ALDH1A1HPGD | |
| SCHEMBL30108233 | 0.83 | PARP1 (0.49) | KDM4ETDP1PARP1ALDH1A1HPGD | |
| SCHEMBL1571384 | 0.82 | MKNK1 (0.55) | KDM4ETDP1PARP1 | |
| SCHEMBL19520186 | 0.82 | PARP1 (0.47) | KDM4ETDP1PARP1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135432-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2007-06-14 | — | — | US | claimed |
| EP-1503993-A4 | COMPOUNDS, METHODS AND COMPOSITIONS | CYTOKINETICS INC (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1503993-A2 | COMPOUNDS, METHODS AND COMPOSITIONS | Cytokinetics, Inc. (US) | 2005-02-09 | — | — | EP | claimed |
| US-20040077662-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2003094839-A2 | PYRIMIDINONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-20 | — | — | WO | claimed |
| EP-1539727-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CELLULAR PROLIFERATIVE DISEASES | CYTOKINETICS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-7482343-B2 | Compounds, methods and compositions | CYTOKINETICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070135432-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1539727-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7166595-B2 | Compounds, methods and compositions | CYTOKINETICS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1556357-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7041676-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1539727-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1503993-A2 | COMPOUNDS, METHODS AND COMPOSITIONS | Cytokinetics, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20040116400-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040082567-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040077662-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004006865-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003106426-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003094839-A2 | PYRIMIDINONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077662-A1 | Compounds, methods and compositions | ALPP, PCNA, MKI67 | KDM4E 1929/4885TDP1 1037/4885PARP1 954/4885 |
| US-20070135432-A1 | Compounds, methods and compositions | ALPP, PCNA, MKI67 | KDM4E 1929/4885TDP1 1037/4885PARP1 954/4885 |
| US-20040082567-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | KDM4E 1780/4885TDP1 879/4885PARP1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.